Pfizer shifts focus after lung cancer trial setback, cites early signals in earlier-line patients; BioNTech and BMS report initial activity

Pfizer’s late‑stage trial in non‑small cell lung cancer did not meet its primary endpoint, prompting the company to highlight a post‑hoc analysis that suggests benefit for patients treated earlier in their disease course.

At the same ESMO meeting, BioNTech and Bristol Myers Squibb presented early‑stage data indicating activity for their respective investigational therapies, though details remain limited.

The contrasting outcomes underscore the challenges of oncology development, with firms seeking to leverage any positive signals while acknowledging the need for further validation.